Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2005-07-25
2008-10-07
Kemmerer, Elizabeth C. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S338000, C435S007400, C435S023000
Reexamination Certificate
active
07432044
ABSTRACT:
The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin.
REFERENCES:
patent: 5981830 (1999-11-01), Wu et al.
patent: 6423543 (2002-07-01), Marcotte et al.
patent: 6482630 (2002-11-01), Gan et al.
patent: 2003/0013097 (2003-01-01), Welsh et al.
patent: 2003/0049645 (2003-03-01), Mu et al.
patent: 2003/0175736 (2003-09-01), Chinnaiyan et al.
patent: 2003/0223973 (2003-12-01), O'Brien et al.
patent: 2004/0001801 (2004-01-01), Madison et al.
patent: 2004/0009911 (2004-01-01), Harris et al.
patent: 2004/0132156 (2004-07-01), Parry et al.
patent: WO 02/059373 (2002-08-01), None
patent: WO 02/064839 (2002-08-01), None
patent: WO 2004/009803 (2004-01-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Birchmeier et al., “Met, Metastasis, Motility and More”Nature Reviews Molecular Cell Biology4 :915-925 (2003).
Carmeliet et al., “Physiological consequences of loss of plasminogen activator gene function in mice”Nature368(6470) :419-424 (1994).
Delaria et al., “Characterization of placental bikunin, a novel human serine protease inhibitor”J Biol Chem. 272(18) :12209-12214 (May 2, 1997).
Denda et al., “Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1”J Biol Chem. 277(16) :14053-14059 (Apr. 19, 2002).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa; I. Potent Inhibitors Selected from Libraries by Phage Display”Journal of Biological Chemistry269(35) :22129-22136 (1994).
Dennis et al., “Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display”J Biol Chem. 270(43) :25411-25417 (Oct. 27, 1995).
Dhanasekaran et al., “Delineation of prognostic biomarkers in prostate cancer”Nature412(6849) :822-826 (Aug. 23, 2001).
Gailani et al., “A murine model of factor XI deficiency”Blood Coag. Fibrinol. 8 :134-144 (1997).
Gak et al., “Processing of Hepatocyte Growth Factor to the Heterodimeric Form is Required for Biological Activity”FEBS Letters311(1) :17-21 (1992).
Gmyrek et al., “Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor”Am J Pathol. 159(2) :579-590 (Aug. 2001).
Hamasuna et al., “Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells” Int J Cancer 93:339-3435 (2001).
Hartmann et al., “A Functional Domain in the Heavy Chain of Scatter Factor/Hepatocyte Growth Factor Binds the c-Met Receptor and Induces Cell Dissociation but Not Mitogenesis”Proc. Natl. Acad. Sci. USA89:11574-11578 (Dec. 1992).
Hathaway et al., “Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency”Am J Med. 60(5) :654-664 (May 10, 1976).
Herter et al., “Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers”Biochemical Journal390:124-136 (Apr. 20, 2005).
Huntsman et al., “Comparisin of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy”Am J Pathol. 155(2) :1318-1328 (Aug. 199).
Husten et al., “The active site of blood coagulation factor Xa. Its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex”J Biol Chem. 262(27) :12953-12961 (Sep. 25, 1987).
Kataoka et al., “Activation of Hepatocyte Growth Factor/Scatter Factor in Colorectal Carcinoma”Cancer Research60:6148-6159 (2000).
Kataoka et al., “Conserved expression of hepatocyte Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas”Cancer Lett. 148(2) :127 (Feb. 1, 2000).
Kataoka et al., “Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues”J Histochem Cytochem. 47(5) :673-682 (May 1999).
Kataoka et al., “Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa”Cancer Lett. 128(2) :219-227 (Jun. 19, 1998).
Kawaguchi et al., “Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor”J Biol Chem. 272(44) :27558-27564 (Oct. 31, 1997).
Kazama et al., “Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation”J Biol Chem. 270(1) :66-72 (Jan. 6, 1995).
Kelley et al., “Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity”Biochemistry43(5) :1223-1229 (Feb. 10, 2004).
Kirchhofer et al., “Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2”FEBS Letters579(9) :1945-1950 (Mar. 28, 2005).
Kirchhofer et al., “Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor β-Chain in Met Binding and Signaling”Journal of Biological Chemistry279:39915-39924 (2004).
Kirchhofer et al., “Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1”J Biol Chem. 278(38) :36341-36349 (Sep. 19, 2003).
Knudsen et al., “High expression of the Met receptor in prostate cancer metastasis to bone”Urology60(6) :113-117 (Dec. 2002).
Lee et al., “Activation of Hepatocyte Growth Factor and Urokinase/Plasmingoen Activator by Matriptase, an Epithelial Membrane Serine Protease”Journal of Biological Chemistry275:36720-36725 (2000).
Leytus et al., “A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells”Biochemistry27(3) :1067-1074 (Feb. 9, 1988).
Lin et al., “Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity”J Biol Chem. 274(26) :18231-18236 (Jun. 25, 1999).
Lin et al., “Purification and characterization of a complex containing matriptase and a kunitz-type serine protease inhibitor from human milk”J Biol Chem272(26) :18237-18242 (1999).
List et al., “Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis”Oncogene21(23) :3765-3779 (May 23, 2002).
Lokker et al., “Structure-Function Analysis of Hepatocyte Growth Factor: Identification of Variants that Lack Mitogenic Activity Yet Retain High Affinity Receptor Binding”EMBO Journal11(7) :2503-2510 (1992).
Luo et al., “Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling”Cancer Research61(12) :4683-4688 (Jun. 15, 2001).
Magee et al., “Expression profiling reveals hepsin overexpression in prostate cancer”Cancer Research61(15) :5692-5696 (Aug. 1, 2001).
Mann, K.G., “Biochemistry and Physiology of Blood Coagulation”Thrombosis and Haemostasis82:165-174 (1999).
Marlor et al., “Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains”J Biol Chem. 272(18) :12202-12208 (May 2, 1997).
McCallum et al.,
Kirchhofer Daniel K.
Moran Paul M.
Peek Mark D.
Borgeest Christina
Coburn Cara M.
Genentech Inc.
Kemmerer Elizabeth C.
LandOfFree
Methods and compositions for modulating hepatocyte growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating hepatocyte growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating hepatocyte growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4007260